BOSTON & GHENT, Belgium--(BUSINESS WIRE)--Orionis Biosciences, a privately held, clinical-stage life sciences company focused on the rational discovery and development of drug modalities with induced ...
Genentech, a member of the Roche Group (SIX: RO, ROP; OTCQX: RHHBY), announced today that it will showcase key real-world, product and pipeline data from its ophthalmology portfolio at the Association ...
WASHINGTON — Plenty of pharmaceutical executives have decried Democrats’ new drug pricing law as detrimental to the industry. But few are willing to say they may be willing to delay treatments for ...
Genentech, a member of the Roche Group (SIX: RO, ROP; OTCQX: RHHBY), announced today new data from the positive Phase III FENhance 1 and 2 studies, which met their primary endpoint. The studies showed ...
Genentech is honing in on an aspect of the patient community that is too often overlooked — the role of caregivers in managing rare diseases. In a recently-released short film, Genentech tells the ...
Biotechnology company Genentech is expanding its local manufacturing capabilities with a $450 million investment in its Oceanside campus. Genentech was founded in 1976 and has been considered a ...
Genentech, a member of the Roche Group (SIX: RO, ROP; OTCQX: RHHBY), announced the launch of All Eyes on DME, a campaign ...
- Patients on fenebrutinib had low relapse rates with data showing no active brain lesions or disability progression after nearly two years of treatment - - Phase III studies for fenebrutinib in ...
Roche’s Genentech is ending a partnership with Nykode Therapeutics that centered around a clinical-stage cancer vaccine program. Back in 2020, the Roche subsidiary inked a worldwide licensing deal ...
Roche’s Genentech is backing this year’s Walk to End Lupus Now, taking up a sponsorship opportunity claimed by GSK in previous years. The Lupus Foundation of America organizes the nationwide program ...
This week, Genentech filed separate lawsuits against Biogen and Millennium, alleging breach of a license agreement to the Cabilly patents (U.S. Patent No. 6,331,415 and 7,923,221). The patents are ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results